

Freedom of Information Request: Our Reference CTMUHB_263_25

You asked:

How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Etrasimod
- Filgotinib
- Golimumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Mirikizumab
- Ozanimod
- Risankizumab
- Tofacitinib
- Upadacitinib
- Ustekinumab - Stelara
- Ustekinumab Biosimilar
- Vedolizumab

Our response:

Please find below a table populated with the information Medicines Management are able to provide at this current time. The period the data relates to latest three months available 1st March 2025 to the 31st May 2025 as requested.

Medicine	Number of Patients
Adalimumab - Humira	**
Adalimumab Biosimilar	239
Etrasimod	0
Filgotinib	**
Golimumab	0
Infliximab - Remicade	**
Infliximab Biosimilar	258
Mirikizumab	0
Ozanimod	0
Risankizumab	31
Tofacitinib	**
Upadacitinib	35
Ustekinumab - Stelara	8

Ustekinumab Biosimilar	169
Vedolizumab	216

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This